Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Tiziana Life Sciences Ltd TLSA

Healthcare Biotechnology
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1... see more

Current News (NDAQ:TLSA)

Tiziana Life Sciences Plans to Spinout IL-6 Asset into Separate Listed Company

GlobeNewswire 7 days ago

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

GlobeNewswire November 25, 2025

Tiziana Life Sciences to Present at Jefferies Global Healthcare Conference

GlobeNewswire November 13, 2025

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

GlobeNewswire November 4, 2025

Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy

GlobeNewswire October 29, 2025

Tiziana Life Sciences Invited to Attend Life Sciences Innovation Forum 2025 in Riyadh, Saudi Arabia

GlobeNewswire September 30, 2025

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

GlobeNewswire September 25, 2025

Tiziana Life Sciences Announces Poster Presentation on Intranasal Foralumab Clinical Trial at the 41st ECTRIMS Congress

GlobeNewswire September 24, 2025

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

GlobeNewswire September 15, 2025
View More News ››

Opinion & Analysis (NDAQ:TLSA)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:TLSA)

Be the first to post on this bullboard.

Nurcapital Capital Pool

Nurcapital Capital Pool

Nurcapital Corporation Ltd. is a Canada-based capital pool company. The Company is engaged in identifying and evaluating ...
View More »